Pharma Major Lupin Limited (Lupin) announced that it has received final approval for its Desoximetasone Cream USP, 0.05% and Desoximetasone Cream USP, 0.25% from the United States Food and Drug Administration (FDA) to market a generic equivalent of Taro Pharmaceuticals North America, Incs Topicort LP Emollient Cream, 0.05% and Taro Pharmaceuticals, Incs (collectively Taro) Topicort® Cream, 0.25%.

Both products are indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.

Topicort® LP emollient Cream had US sales of USD 33 mn (IMS MAT September 2016) while Topicort Cream had US sales of USD 17 mn (IMS MAT September 2016).

Like

Dislike

Be a part of Elets Collaborative Initiatives. Join Us for Upcoming Events and explore business opportunities. Like us on Facebook , connect with us on LinkedIn and follow us on Twitter , Instagram.